ENTRY       D02994                      Drug
NAME        Rituximab (USAN/INN);
            Rituximab (genetical recombination) (JAN);
            Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN);
            Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN);
            Rituximab-abbs;
            Rituximab-pvvr;
            Rituximab-arrx;
            Rituxan (TN);
            Riabni (TN);
            Truximab (TN)
PRODUCT     RIABNI (Amgen)
            RITUXAN (Genentech)
            RUXIENCE (Pfizer Laboratories Div Pfizer)
            TRUXIMA (Cephalon)
REMARK      Therapeutic category: 4291
            ATC code: L01FA01
            Product: D02994<JP/US>
            Product (mixture): D11393<US>
EFFICACY    Antineoplastic, Anti-CD20 antibody
  DISEASE   Non-Hodgkin's lymphoma (CD20-positive) [DS:H02418]
            Chronic lymphocytic leukemia (CD20-positive) [DS:H00005]
            Rheumatoid arthritis [DS:H00630]
            Granulomatosis with polyangiitis; Wegener's granulomatosis [DS:H01655]
            Microscopic polyangiitis [DS:H01658]
            Pemphigus vulgaris [DS:H01648]
  TYPE      Monoclonal antibody
TARGET      CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(931)  Hematopoietic cell lineage
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FA CD20 (Clusters of Differentiation 20) inhibitors
                 L01FA01 Rituximab
                  D02994  Rituximab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Rituximab
                D02994  Rituximab (USAN/INN)
             Immunological Agents
              Immunosuppressants
               Immunosupressants, Other
                Rituximab
                 D02994  Rituximab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D02994  Rituximab (USAN/INN); Rituximab (genetical recombination) (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD20
                 D02994  Rituximab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02994
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02994
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D02994
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D02994
DBLINKS     CAS: 174722-31-7
            PubChem: 17397150
            NIKKAJI: J1.653.613J
///
